American Century Companies Inc. Acquires 15,079 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

American Century Companies Inc. raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 866,366 shares of the biopharmaceutical company’s stock after acquiring an additional 15,079 shares during the quarter. American Century Companies Inc. owned about 0.68% of Halozyme Therapeutics worth $41,421,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Heck Capital Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth about $29,000. Smartleaf Asset Management LLC grew its holdings in Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics during the fourth quarter valued at about $69,000. Finally, Parkside Financial Bank & Trust boosted its position in shares of Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 322 shares during the period. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 1.0 %

HALO opened at $64.48 on Friday. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The business’s fifty day simple moving average is $58.98 and its 200 day simple moving average is $54.85. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $66.00. The stock has a market cap of $7.97 billion, a PE ratio of 18.80, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total value of $293,450.00. Following the transaction, the director now owns 33,611 shares in the company, valued at $1,972,629.59. This trade represents a 12.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at $10,765,546.65. This represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of analyst reports. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Benchmark restated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.